688443 智翔金泰-U
交易中 09-15 11:23:09
资讯
新帖
简况
股市必读：智翔金泰（688443）9月4日董秘有最新回复
证券之星 · 09-07
股市必读：智翔金泰（688443）9月4日董秘有最新回复
每周股票复盘：智翔金泰（688443）营收增237.29%
证券之星 · 09-06
每周股票复盘：智翔金泰（688443）营收增237.29%
智翔金泰（688443）披露2026年半年度报告，8月31日股价下跌2.23%
证券之星 · 08-31
智翔金泰（688443）披露2026年半年度报告，8月31日股价下跌2.23%
智翔金泰2026年半年报：核心产品放量营收翻倍，亏损幅度扩大
蓝鲸财经 · 08-31
智翔金泰2026年半年报：核心产品放量营收翻倍，亏损幅度扩大
智翔金泰(688443)6月30日股东户数1.32万户，较上期增加2.84%
证券之星 · 08-30
智翔金泰(688443)6月30日股东户数1.32万户，较上期增加2.84%
每周股票复盘：智翔金泰（688443）纬利妥米单抗附条件获批上市
证券之星 · 08-30
每周股票复盘：智翔金泰（688443）纬利妥米单抗附条件获批上市
智翔金泰：纬利妥米单抗注射液获附条件批准上市
证券之星 · 08-27
智翔金泰：纬利妥米单抗注射液获附条件批准上市
每周股票复盘：智翔金泰（688443）GR2302注射液获两项临床试验批准
证券之星 · 08-23
每周股票复盘：智翔金泰（688443）GR2302注射液获两项临床试验批准
智翔金泰：GR2302注射液慢性乙型肝炎适应症获临床试验批准
格隆汇 · 08-18
智翔金泰：GR2302注射液慢性乙型肝炎适应症获临床试验批准
智翔金泰（688443）披露GR2302注射液获临床试验批准通知书，8月18日股价上涨1.11%
证券之星 · 08-18
智翔金泰（688443）披露GR2302注射液获临床试验批准通知书，8月18日股价上涨1.11%
智翔金泰：GR2302注射液获药物临床试验批准通知书
证券之星 · 08-17
智翔金泰：GR2302注射液获药物临床试验批准通知书
股市必读：智翔金泰（688443）7月24日董秘有最新回复
证券之星 · 07-27
股市必读：智翔金泰（688443）7月24日董秘有最新回复
股市必读：智翔金泰（688443）7月17日董秘有最新回复
证券之星 · 07-20
股市必读：智翔金泰（688443）7月17日董秘有最新回复
智翔金泰(688443.SH)：泰利奇拜单抗注射液成人中、重度特应性皮炎适应症上市申请获受理
智通财经 · 07-16
智翔金泰(688443.SH)：泰利奇拜单抗注射液成人中、重度特应性皮炎适应症上市申请获受理
每周股票复盘：智翔金泰（688443）撤回特应性皮炎药注册申请
证券之星 · 07-05
每周股票复盘：智翔金泰（688443）撤回特应性皮炎药注册申请
智翔金泰（688443）披露关于撤回药品注册申请的公告，7月01日股价上涨4.43%
证券之星 · 07-01
智翔金泰（688443）披露关于撤回药品注册申请的公告，7月01日股价上涨4.43%
股市必读：智翔金泰（688443）6月26日董秘有最新回复
证券之星 · 06-29
股市必读：智翔金泰（688443）6月26日董秘有最新回复
智翔金泰（688443）2671万股限售股将于6月24日解禁，占总股本7.28%
证券之星 · 06-24
智翔金泰（688443）2671万股限售股将于6月24日解禁，占总股本7.28%
智翔金泰（688443）披露斯乐韦米单抗注射液获批上市，6月22日股价下跌2.56%
证券之星 · 06-22
智翔金泰（688443）披露斯乐韦米单抗注射液获批上市，6月22日股价下跌2.56%
智翔金泰(688443.SH)：狂犬病被动免疫制剂“斯乐韦米单抗注射液”获批上市
智通财经 · 06-22
智翔金泰(688443.SH)：狂犬病被动免疫制剂“斯乐韦米单抗注射液”获批上市
暂无数据
公司概况
公司名称：
重庆智翔金泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-06-20
主营业务：
重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、纬利妥米单抗（GR1803）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、GR1603、GR2301、GR2303、GR2302、GR2304、GR2502、GR2603。公司2022年11月28日获得高新技术企业认定证书。
发行价格：
37.88
{"stockData":{"symbol":"688443","market":"SH","secType":"STK","nameCN":"智翔金泰-U","latestPrice":22.16,"timestamp":1789442589000,"preClose":22.45,"halted":0,"volume":653157,"delay":0,"changeRate":-0.0129,"floatShares":143000000,"shares":367000000,"eps":-1.5341,"marketStatus":"交易中","change":-0.29,"latestTime":"09-15 11:23:09","open":22.53,"high":22.53,"low":22.14,"amount":14543900,"amplitude":0.0174,"askPrice":22.18,"askSize":11,"bidPrice":22.16,"bidSize":37,"shortable":0,"etf":0,"ttmEps":-1.5341,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789443000000},"marketStatusCode":2,"adr":0,"adjPreClose":22.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789435800000,1789443000000],[1789448400000,1789455600000]],"highLimit":24.7,"lowLimit":20.21,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":366680000,"isCdr":false,"pbRate":6.42,"roa":"--","roe":"--","epsLYR":-1.46,"committee":0.638554,"marketValue":8126000000,"turnoverRate":0.0046,"status":1,"floatMarketCap":3178000000},"requestUrl":"/m/hq/s/688443/tweets","defaultTab":"tweets","newsList":[{"id":"2665622653","title":"股市必读：智翔金泰（688443）9月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2665622653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665622653?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:03","pubTimestamp":1788714193,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，智翔金泰报收于23.25元，下跌1.23%，换手率2.0%，成交量2.87万手，成交额6745.0万元。截至2026年9月4日，公司已收到斯乐韦米单抗注射液上市里程碑付款，相关情况敬请您关注公司后续披露的定期报告。根据《GR1801注射液独家合作协议》，公司将获得斯乐韦米单抗注射液中国大陆区域销售收入，该部分销售收入公司将按照《企业会计准则》相关规定确认营业收入。半年度报告的营业收入未包含BD许可收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365274","title":"每周股票复盘：智翔金泰（688443）营收增237.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365274","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365274?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:29","pubTimestamp":1788632949,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，智翔金泰报收于23.25元，较上周的24.22元下跌4.0%。本周，智翔金泰8月31日盘中最高价报24.6元。本周关注点来自业绩披露要点：报告期内，公司实现营业收入153,101,666.19元，较上年同期增长237.29%。公司公告汇总重庆智翔金泰生物制药股份有限公司2026年半年度报告摘要显示，公司代码688443，公司简称智翔金泰。2026年上半年实现营业收入15,310.17万元，同比增长237.29%；研发费用24,190.98万元，同比增长10.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663655072","title":"智翔金泰（688443）披露2026年半年度报告，8月31日股价下跌2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663655072","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663655072?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:34","pubTimestamp":1788172499,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，智翔金泰报收于23.68元，较前一交易日下跌2.23%，最新总市值为86.83亿元。该股当日开盘23.88元，最高24.6元，最低23.58元，成交额达8398.53万元，换手率为2.46%。公司于近日披露《2026年半年度报告》。研发投入占营业收入的比例为158.01%。总资产为2,739,111,981.25元，较上年度末下降8.49%；归属于上市公司股东的净资产为1,281,547,457.57元，较上年度末下降19.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079098","title":"智翔金泰2026年半年报：核心产品放量营收翻倍，亏损幅度扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079098","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663079098?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:49","pubTimestamp":1788169742,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月31日讯，8月30日，智翔金泰 公布2026年中报，公司依托核心产品赛立奇单抗纳入医保后的放量效应，受益于自身免疫性疾病领域商业化进程加速，报告期营收实现翻倍式增长；与此同时，公司持续保持高强度研发投入并推进多管线临床进展，虽亏损幅度有所扩大，但现金储备依然充裕，商业化与研发双轮驱动格局进一步夯实。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788148444170794855","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049467","title":"智翔金泰(688443)6月30日股东户数1.32万户，较上期增加2.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049467","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663049467?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080878,"startTime":"0","endTime":"0","summary":"证券之星消息，近日智翔金泰披露，截至2026年6月30日公司股东户数为1.32万户，较3月31日增加365.0户，增幅为2.84%。在生物制品行业个股中，智翔金泰股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.54万户。从股价来看，2026年3月31日至2026年6月30日，智翔金泰区间跌幅为9.39%，在此期间股东户数增加365.0户，增幅为2.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010022","title":"每周股票复盘：智翔金泰（688443）纬利妥米单抗附条件获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010022","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010022?lang=zh_cn&edition=full","pubTime":"2026-08-30 04:44","pubTimestamp":1788036251,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，智翔金泰报收于24.22元，较上周的25.95元下跌6.67%。本周，智翔金泰8月28日盘中最高价报26.5元。本周关注点来自公司公告汇总：纬利妥米单抗注射液获国家药监局附条件批准上市。公司公告汇总自愿披露关于纬利妥米单抗注射液附条件批准上市的公告重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，批准公司自主研发的纬利妥米单抗注射液附条件上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704554","title":"智翔金泰：纬利妥米单抗注射液获附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704554","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662704554?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:33","pubTimestamp":1787830433,"startTime":"0","endTime":"0","summary":"智翔金泰(688443.SH)公告称，公司收到国家药监局核准签发的《药品注册证书》，批准自主研发的纬利妥米单抗注射液(GR1803注射液，商品名：维可妥)附条件上市。该药品适用于既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700046345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661067211","title":"每周股票复盘：智翔金泰（688443）GR2302注射液获两项临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661067211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661067211?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:54","pubTimestamp":1787424850,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，智翔金泰报收于25.95元，较上周的26.36元下跌1.56%。本周，智翔金泰8月20日盘中最高价报27.7元。自愿披露关于GR2302注射液慢性乙型肝炎适应症获得药物临床试验批准通知书的公告重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，其自主研发的GR2302注射液获准开展慢性乙型肝炎适应症的临床试验。截至目前，国内尚无同靶点药物获批开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461741","title":"智翔金泰：GR2302注射液慢性乙型肝炎适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461741","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660461741?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:18","pubTimestamp":1787051901,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660946505","title":"智翔金泰（688443）披露GR2302注射液获临床试验批准通知书，8月18日股价上涨1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660946505","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660946505?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:35","pubTimestamp":1787045738,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，智翔金泰报收于26.44元，较前一交易日上涨1.11%，最新总市值为96.95亿元。该股当日开盘26.45元，最高27.15元，最低26.2元，成交额达1.33亿元，换手率为3.49%。近日，重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司GR2302注射液单药在乙肝病毒相关肝细胞癌患者中开展临床试验。截至目前，国内尚无同靶点药物获批开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487858","title":"智翔金泰：GR2302注射液获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487858","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660487858?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:59","pubTimestamp":1786967989,"startTime":"0","endTime":"0","summary":"智翔金泰(688443.SH)公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，在研产品GR2302注射液临床试验申请获得批准。该药品适应症为乙肝病毒相关肝细胞癌，是一款基于TCR模拟抗体和抗CD3抗体的双特异性抗体，能够招募T细胞杀伤被HBV感染的肝细胞。截至公告披露日，暂无同靶点药物在国内获批开展临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700030231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654061026","title":"股市必读：智翔金泰（688443）7月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654061026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654061026?lang=zh_cn&edition=full","pubTime":"2026-07-27 01:35","pubTimestamp":1785087310,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，智翔金泰报收于23.35元，下跌4.3%，换手率2.16%，成交量3.1万手，成交额7392.24万元。董秘最新回复投资者： 按合同约定，药友公司应在合同生效后即付首付款。截至2026年7月24日，公司已收到GR1803项目许可协议首付款3亿元。交易信息汇总资金流向7月24日主力资金净流出572.17万元，占总成交额0.0%；游资资金净流入426.68万元，占总成交额0.0%；散户资金净流入145.49万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700000770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652325787","title":"股市必读：智翔金泰（688443）7月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2652325787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652325787?lang=zh_cn&edition=full","pubTime":"2026-07-20 01:58","pubTimestamp":1784483888,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，智翔金泰报收于23.73元，下跌8.2%，换手率3.72%，成交量5.34万手，成交额1.31亿元。公司公告汇总自愿披露关于泰利奇拜单抗注射液成人中、重度特应性皮炎适应症上市申请获得受理的公告重庆智翔金泰生物制药股份有限公司就泰利奇拜单抗注射液用于成人中、重度特应性皮炎适应症向国家药品监督管理局药品审评中心提交新药上市申请，并获得受理。该上市申请尚需经过审评、现场检查及审批等环节。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000000958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651417537","title":"智翔金泰(688443.SH)：泰利奇拜单抗注射液成人中、重度特应性皮炎适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2651417537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651417537?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:38","pubTimestamp":1784191082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰 发布公告，近日，公司就泰利奇拜单抗注射液用于成人中、重度特应性皮炎适应症向国家药品监督管理局药品审评中心提交了新药上市申请并获得受理。泰利奇拜单抗注射液能特异性结合细胞表面人IL-4Rα，阻断IL-4、IL-13与IL-4Rα的结合，抑制下游STAT6磷酸化，抑制CD23上调，从而抑制由IL-4或IL-13介导的Th2型炎症反应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688443","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649142694","title":"每周股票复盘：智翔金泰（688443）撤回特应性皮炎药注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2649142694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649142694?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:29","pubTimestamp":1783189750,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，智翔金泰报收于25.2元，较上周的21.43元上涨17.59%。公司公告汇总自愿披露关于撤回药品注册申请的公告重庆智翔金泰生物制药股份有限公司主动申请撤回泰利奇拜单抗注射液用于成人中、重度特应性皮炎适应症的药品注册申请，并获国家药品监督管理局药品审评中心同意。该撤回不涉及药物安全性与疗效问题，公司将在近期重新提交注册申请。泰利奇拜单抗注射液其他适应症的新药上市申请已获受理或处于不同临床试验阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648511272","title":"智翔金泰（688443）披露关于撤回药品注册申请的公告，7月01日股价上涨4.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648511272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648511272?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:55","pubTimestamp":1782899713,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，智翔金泰报收于24.28元，较前一交易日上涨4.43%，最新总市值为89.03亿元。该股当日开盘22.86元，最高24.4元，最低22.02元，成交额达1.81亿元，换手率为5.42%。公司于近日披露《自愿披露关于撤回药品注册申请的公告》。该撤回不涉及药物安全性与疗效问题，公司将在近期重新提交注册申请。泰利奇拜单抗注射液其他适应症的新药上市申请已获受理或处于不同临床试验阶段。本次撤回对公司整体研发、当期生产经营和业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647345596","title":"股市必读：智翔金泰（688443）6月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647345596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647345596?lang=zh_cn&edition=full","pubTime":"2026-06-29 04:22","pubTimestamp":1782678133,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，智翔金泰报收于21.43元，下跌3.34%，换手率3.51%，成交量5.03万手，成交额1.08亿元。董秘最新回复投资者： 董秘，你好，根据我长期跟踪贵司经营情况，我预计贵司2026年半年报业绩将大幅增长，请问贵司是否会主动披露业绩预报？公司唯康度塔单抗注射液、泰利奇拜单抗注射液、纬利妥米单抗注射液的上市申请均处于正常审评阶段，后续进展敬请关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900001361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645850546","title":"智翔金泰（688443）2671万股限售股将于6月24日解禁，占总股本7.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645850546","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645850546?lang=zh_cn&edition=full","pubTime":"2026-06-24 08:01","pubTimestamp":1782259287,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，智翔金泰于6月24日将有2671.0万股限售股份解禁，为公司首发原股东限售股份，占公司总股本7.28%。本次解禁后，公司还有2.23亿股限售股份，占总股本60.9%。智翔金泰主营业务：抗体药物的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400007529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073985","title":"智翔金泰（688443）披露斯乐韦米单抗注射液获批上市，6月22日股价下跌2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073985","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645073985?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:31","pubTimestamp":1782138678,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，智翔金泰报收于21.29元，较前一交易日下跌2.56%，最新总市值为78.07亿元。该股当日开盘21.69元，最高21.8元，最低20.07元，成交额达1.42亿元，换手率为5.88%。近日，重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，批准其自主研发的1类新药斯乐韦米单抗注射液上市，用于成人狂犬病病毒暴露者的被动免疫。公司已与康哲药业签署独家合作协议，授予其中国大陆及部分亚太地区的商业化权利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200038999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645047633","title":"智翔金泰(688443.SH)：狂犬病被动免疫制剂“斯乐韦米单抗注射液”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645047633","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645047633?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:18","pubTimestamp":1782116326,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)公告，公司收到国家药品监督管理局核准签发的《药品注册证书》，批准公司自主研发用于成人狂犬病病毒暴露者的被动免疫适应症的1类新药斯乐韦米单抗注射液(商品名：金速希)上市。据悉，斯乐韦米单抗注射液是全球首款针对狂犬病病毒双表位的全人源双特异性抗体，可大规模标准化稳定生产。同时，该产品也是目前剂量最小的狂犬病被动免疫制剂，用量少，易推注，可有效减轻患者疼痛感，提高依从性，分子设计符合WHO推荐的“鸡尾酒式”疗法，其上市有望给患者提供多方位保护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688443","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789442593926,"stockEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":-0.1483},{"period":"3month","weight":0.06},{"period":"6month","weight":-0.167},{"period":"1year","weight":-0.3434},{"period":"ytd","weight":-0.1758}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智翔金泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13208人(较上一季度增加2.84%)","perCapita":"10856股","listingDate":"2023-06-20","address":"重庆市巴南区麻柳大道699号2号楼A区","registeredCapital":"36668万元","survey":" 重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、纬利妥米单抗（GR1803）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、GR1603、GR2301、GR2303、GR2302、GR2304、GR2502、GR2603。公司2022年11月28日获得高新技术企业认定证书。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智翔金泰-U,688443,智翔金泰-U股票,智翔金泰-U股票老虎,智翔金泰-U股票老虎国际,智翔金泰-U行情,智翔金泰-U股票行情,智翔金泰-U股价,智翔金泰-U股市,智翔金泰-U股票价格,智翔金泰-U股票交易,智翔金泰-U股票购买,智翔金泰-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}